James A. Bannon, PharmD

President, Scientific & Regulatory Review Division


Photo of Jim Bannon

Dr. Bannon joined WCG in 2017 when Vigilare International, a leading provider of drug safety and pharmacovigilance solutions was acquired. At that time, Dr Bannon was the founder and CEO of Vigilare International.

In 2018, he was promoted to his new role as president, scientific review division for WCG. In this role, Dr. Bannon is responsible for the full range of global drug safety and pharmacovigilance services, including individual case safety reports (ICSR), aggregate safety reporting, data safety committees, safety report distribution, risk management, signal detection, and regulatory safety reporting.

With more than 25 years’ clinical research experience, Dr. Bannon has held positions of increasing responsibility in operations and executive management.

Prior to Vigilare International, Dr. Bannon was executive chairman of IndiPharm, Inc., a global regional clinical research and training organization, for six years. IndiPharm provided high quality research services for western biopharmaceutical companies conducting clinical studies in India and the ASEAN nations.

Previously, Dr. Bannon worked for Covance for more than 15 years, initially as general manager, peri-approval services, and later as group president for several of its late-stage businesses including clinical phase 2/3, central diagnostics, IVRS and peri-approval services. Those businesses delivered clinical trial services globally to more than 35 countries.

Dr. Bannon received his PharmD and BS in pharmacy from the Philadelphia College of Pharmacy and Science.